Core Viewpoint - The article introduces innovative solutions for cell transfection challenges, emphasizing breakthroughs in technology that enhance efficiency and success rates in scientific research [2]. Group 1: Innovations in Cell Transfection - The introduction of a capillary-type electric chamber provides a more uniform electric field, resulting in a 2-3 times increase in survival rates for difficult-to-transfect cells such as primary and stem cells [3]. - The third-generation Extransfection™ electroporation device features an intelligent parameter matrix that allows for one-click operation, significantly improving transfection efficiency with over 300 validated transfection conditions [5]. - The device simplifies the transfection process into three steps: sample preparation, electroporation, and cell culture, making it accessible for beginners to produce publishable data [8]. Group 2: Targeting Difficult Transfection Scenarios - The technology effectively addresses challenges in gene editing, achieving a 90% delivery efficiency for Cas9 in CRISPR-Cas9 RNP transfections, thus facilitating advancements in gene research, cell modification, and vaccine development [9]. Group 3: Company Overview - Suzhou Quictek Biotechnology Co., Ltd. is a high-tech enterprise based in the Yangtze River Delta, serving nationwide needs and is the exclusive partner of Korea's NanoEnTek in China [18]. - The company focuses on providing solutions for cell and molecular biology research, offering high-end laboratory consumables and equipment, as well as customized technical services [19]. - Quictek holds a 30% market share in the global cell counting instrument market and has received 11 FDA 510(k) certifications, with products distributed in over 70 countries [20].